The international team of researchers has successfully tested Ion224, a new drug designed to combat fatty liver disease. The results of the study were published in The Lancet magazine.
The study was attended by 160 patients from the United States and Puerto Rico, who had the approved metabolism of the stesying-in-law and liver fibrosis.
Mash, or non-alcoholic steateophatite, is a progressive liver disease associated with metabolism disorders such as obesity, diabetes and dispersion. It develops when excess fat accumulates in the liver, which leads to inflammation and liver cell damage.
The first group of participants received the drug for 51 weeks, a month, with different doses. The data of the controller group received by the placebo have also included.
ION224 works, blocking the DGat2 enzyme, which is responsible for the occurrence of fat sediments in the liver and is associated with inflammation and cell damage. According to the received data, the liver function was improved by 59% of the recipients of 120 mg per 90 mg per capitators. For comparison, only 19% of the participants of the placebo group had an improvement.
The main feature of therapy was that the positive effect was obtained from the loss of an independent weight. According to scientists, this opens it to other drugs, including GLP-1 medicines, such as Ozzemp, with combined therapy.
Scientists note that non-alcoholic stesyatolitis is one of the main reasons for liver cirrhosis and transplantation. Researchers hope that the use of ION224 will help reduce the need for such surgeries in the future.
Translation of: Euromedia24.com
